Search

Displaying results 3191 - 3200 of 3917 in total
  1. Drug

    IMCY-0141

    go.drugbank.com/drugs/DB17019
    Investigational

    IMCY-0141 is a synthetic peptide based on MOG (Myelin Oligodendrocyte Glycoprotein), a dominant autoantigen, designed to stop the progression of multiple sclerosis (MS) and the destruction of the myelin

  2. Drug

    Maytansine

    go.drugbank.com/drugs/DB19582
    Investigational

    Maytansine is under investigation in clinical trial NCT04189211 (A Clinical Trial of BAT8001 on Safety, Tolerability and Pharmacokinetics for Patients).

  3. Drug

    RD06-04

    go.drugbank.com/drugs/DB24647
    Investigational

    RD06-04 is under investigation in clinical trial NCT06986018 (Clinical Study on the Targeted CD19 Universal CAR-T Cell Injection (RD06-04) for the Treatment of IIM and AAV).

  4. Drug

    Tipapkinogene sovacivec

    go.drugbank.com/drugs/DB06239
    Investigational

  5. Drug

    Glisoxepide

    go.drugbank.com/drugs/DB01289
    Investigational

    Glisoxepide is one of the sulphonamide-derived oral antidiabetic drugs. It inhibits the uptake of bile acids into isolated rat hepatocytes. However it inhibits taurocholate uptake only in the absence of sodium ions. Glisoxepide uptake co...

  6. Drug

    Difloxacin

    go.drugbank.com/drugs/DB11511
    ExperimentalVet approved

    As an antibacterial, it presents a broad bactericidal spectrum and its effects are dependent on its concentration.

  7. Drug

    Ostabolin-C

    go.drugbank.com/drugs/DB05536
    Investigational

    Ostabolin C was under investigation in clinical trial NCT00787358 (A Proof-of-Concept Study Investigating the Safety and Efficacy of ZT-031 on Hip Fracture Healing in Men and Postmenopausal Women (SHIFT

  8. Drug

    Denileukin diftitox

    go.drugbank.com/drugs/DB00004
    ApprovedInvestigational

    A264344] In 2014, it was withdrawn voluntarily from the market due to manufacturing issues; however, the biologics license application (BLA) for denileukin diftitox was resubmitted, and it was approved on

  9. Drug

    Pirbuterol

    go.drugbank.com/drugs/DB01291
    ApprovedWithdrawn

    In vitro studies and in vivo pharmacologic studies have demonstrated that pirbuterol has a preferential effect on beta-2 Adrenergic receptors compared with isoproterenol.

  10. Drug

    Pafolacianine

    go.drugbank.com/drugs/DB15413
    ApprovedInvestigational

    [A242572] On November 29, 2021, the FDA approved pafolacianine as an adjunct imaging agent for intraoperative identification of malignant lesions in adult patients with ovarian cancer.